As Erasca’s vice president of data science, Jing brings 15 years of experience in biometrics and drug development. Prior to Erasca, she took on a variety of roles of increasing responsibility at Roche/Genentech, most recently as the global development lead and group clinical science director, accountable for the overarching development strategy and program leadership of Tecentriq® in lung cancer and head and neck cancer. Jing was previously a biostatistics manager and biometrics lead at Roche/Genentech overseeing cancer immunotherapy products across a broad range of cancer types. She helped advance the development of tiragolumab in lung and head and neck cancer and Tecentriq® across various tumor types, including achieving breakthrough therapy designation and global registration for bladder and lung cancer as well as multiple line extensions. She supported Avastin® development and post-marketing programs across multiple oncology disease areas. She also represented biometrics at the Roche lung and cancer immunotherapy portfolio level and co-led multiple cross-oncology and cross-pharmaceutical initiatives.
Jing received her Ph.D. in statistics from the University of California, Berkeley and her B.S. in computational mathematics from the Qingdao University.